The biological responses and mechanisms of endothelial cells to magnesium alloy

Zhe Hou1, Maolong Xiang2, Nuoya Chen1, Xiao Cai3, Bo Zhang1, Rifang Luo1, Li Yang1, Xiaoyi Ma4, Lifeng Zhou4, Fugui He4, Hongchi Yu1,5,* and Yunbing Wang1,*

1National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China; 2College of Life Sciences, Sichuan University, Chengdu 610064, China; 3The Fourth People’s Hospital of Chengdu, Chengdu 610036, China; 4Beijing Key Laboratory of Cardiac Drug Device Technology and Evidence Based Medicine, Beijing 100021, China; and 5Institute of Biomedical Engineering, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China

*Correspondence address. National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China. E-mail: yuhongchi@scu.edu.cn and yunbing.wang@scu.edu.cn

Received 9 December 2020; revised 22 March 2021; accepted on 5 April 2021

Abstract

Due to its good biocompatibility and degradability, magnesium alloy (Mg alloy) has shown great promise in cardiovascular stent applications. Rapid stent re-endothelialization is derived from migrated and adhered endothelial cells (ECs), which is an effective way to reduce late thrombosis and inhibit hyperplasia. However, fundamental questions regarding Mg alloy affecting migration and adhesion of ECs are not fully understood. Here, we evaluated the effects of Mg alloy on the ECs proliferation, adhesion and migration. A global gene expression profiling of ECs co-culturing with Mg alloy was conducted, and the adhesion- and migration-related genes were examined. We found that Mg alloy had no adverse effects on ECs viability but significantly affected ECs migration and adhesion. Co-cultured with Mg alloy extract, ECs showed contractive adhesion morphology and decreased motility, which was supported by the down-regulation of adhesion-related genes (Paxillin and Vinculin) and migration-related genes (RAC 1, Rho A and CDC 42). Accordingly, the re-endothelialization of Mg alloy stent was inhibited in vivo. Our results may provide new inspiration for improving the broad application of Mg alloy stents.

Keywords: magnesium alloy; endothelial cells; migration; adhesion

Introduction

Cardiovascular disease (CVD), which is characterized by high morbidity, high mortality and high disability rate, is the leading cause of death in the world [1]. Coronary heart disease counts for 43.2% of deaths attributable to CVD [2]. Coronary artery bypass graft (CABG) can completely vascularize the diseased part. However, after CABG surgery, the ratio of saphenous vein grafts occlusion arrives 10–25% from thrombosis within 1 year, and an additional 1–2% occlude from 1 to 5 years after CABG surgery [3]. Percutaneous transluminal coronary angioplasty with a coronary stent has been the routine treatment for coronary artery disease (CAD) [4]. However, in-stent restenosis (ISR) appears as the main problem after the bare-metal stent (BMS) implantation [5, 6]. Increasing evidence shows that intimal neogenesis, which is marked by excessive vascular smooth muscle cells (VSMCs) proliferation, is the decisive contributor to ISR [7, 8]. Accordingly, the drug-eluting stent (DES) is applied for suppressing the excessive proliferation of VSMCs to alleviate ISR [9, 10]. Despite that, the loading drugs, such as rapamycin (sirolimus) and paclitaxel, repress the excessive proliferation of VSMCs, but they also induce dysfunction of endothelial cells (ECs), which contributes to the delayed re-endothelialization and late stent thrombosis (LST) [11–16]. Biodegradable materials may disappear completely, thus avoid some lifelong problems caused by permanent implants, including permanent physical irritation and local chronic inflammatory reactions [17]. Therefore, it attracts considerable attention in coronary stent application.
With the better combination of strength and ductility compared with biodegradable polymer materials, biodegradable metallic materials, including magnesium (Mg), ferrous (Fe) and zinc (Zn) based alloy, have been proposed as potential materials for coronary stent implantation [18]. With the higher intake dosage daily and similar biomechanical characters to natural tissues [19], Mg-based alloy (Mg alloy) has been successfully used in several clinical trials [20–22]. ECs play an essential role in maintaining the integrity of the vessel by preventing thrombosis and hyperplasia. Basically, arterial injury is an inevitable consequence of stent implantation. Therefore, early and persistent EC coverage of the stent by structurally and functionally normal ECs should be considered the priority after stent implantation [23]. Although the influence of Mg ions on the proliferation of ECs has been shown [24], the effect of Mg alloy on ECs migration and adhesion abilities, which controls the stent re-endothelialization, is still not well known.

Here, we investigated Mg alloy’s effect on ECs migration and adhesion abilities in vitro and in vivo. It revealed that ECs cultured in Mg alloy extract showed contractive adhesion morphology and downregulated motility, which was supported by the down-regulation of adhesion-related genes (Paxillin and Vinculin) and migration-related genes (RAC 1, Rho A and CDC 42). On the surface of implanted Mg alloy in rabbits, ECs showed less attachment. Collectively, our data indicated that the adhesion and migration of ECs were deregulated by Mg alloy, resulting in the retarded re-endothelialization.

Materials and methods

Cell culture

Human coronary artery endothelial cells (HCAECs) were purchased from ScienCell™ (San Diego, CA, USA) and cultured in endothelial cell medium (ScienCell™), at 37°C, saturated humidity and 5% CO₂. The medium included 500 mL of basal medium, 25 mL of fetal bovine serum (ScienCell™), 5 mL of EC growth supplement (ECGS, ScienCell™) and 5 mL of penicillin/streptomycin solution (P/S, ScienCell™). The cells were used for subsequent experiments when they formed a single layer.

Mg alloy preparation

Mg alloy discs (10 mm × 2 mm) and stents (Ø 2 × 18 mm) were obtained from Beijing Amsino Medical Co., Ltd. The Mg alloy component contained Gd 3.5–5.5 wt%, Y 1.5–4.5 wt%, Zn 0–2.0 wt%, Zr 0–2.0 wt%. The metal discs were polished with SiC paper and cleaned ultrasonically in an acetone bath for 10 min. Before cell seeding, the metal discs were sterilized.

Mg alloy extract medium preparation

The metal discs were sterilized and put into a 50-mL centrifuge tube. The Mg alloy extract was prepared using a serum-free endothelial cell medium with the surface area of extract medium ratio of 1.25 cm²/mL [25, 26] and incubated in a 37°C incubator with supplementation of 5% CO₂ for 7 days.

Stent implantation

The New Zealand rabbits (3.0–3.5 kg) used in the present study were purchased from DaShuo experimental animal Co. Ltd (Chengdu, China) and approved by the medical ethics committee of Sichuan University. Male rabbits were used in all in vivo studies. Each stent was hand-crimped on a 3.0 mm angioplasty balloon and intervened into the artery from the proximal iliac artery and then deployed (8-atm balloon inflation for 45 s) in the artery, achieving an approximate balloon to artery ratio of 1.2:1. Ultrasonic imaging (VINNO 6LAB, Vinno, China) was used to validate the stent’s proper location. The rabbits received 40 mg of aspirin orally 24 h before surgery and daily after that. Euthanasia was performed at 7, 14 and 28 days (n = 3 in every group) after stent deployment.

Subcutaneous implantation

For measuring the biodegradation of Mg alloy in vivo, subcutaneous implantation was conducted. The rats used in the present study were purchased from DaShuo experimental animal Co. Ltd (Chengdu, China) and approved by the Medical Ethics Committee of Sichuan University. All in vivo studies were conducted in male rats. The animals were kept at a constant temperature (21 ± 1°C) under 12/12-h light/dark cycle and had free access to water and standard chow. Briefly, freshly prepared Mg alloy discs were implanted into individual dorsal subcutaneous pockets. Animals were euthanized after implanting 7, 14 or 28 days.

Cell proliferation assay

HCAECs were plated at a density of 2000 cells/µL in a 96-well plate (100 µL/well) and incubated in a 37°C incubator with supplementation of 5% CO₂. After incubation for 24h, Mg alloy extract medium (100 µL) was added into the well and incubated for another 24h, the final dilution of extract medium was 50%. According to the manufacturer’s instruction, cell proliferation was assessed using the CCK-8 assay (Sigma-Aldrich, USA). CCK-8 solution was added equal to 1/10 the media volume, and the incubation time was 2 h. Then, 10 µL of 1% SDS was used to stop the colour development reaction. The absorbance at 450 nm was measured.

Scanning electron microscope

The surface morphology of Mg alloy after degradation in vivo or in vitro was viewed. The cell samples were fixed by 4% paraformaldehyde buffer after cultured 24 h on the Mg alloy discs and dehydrated by gradient concentrations (75%, 90% and 100%) of ethanol for 5 min each time and dried. Then, cell morphologies were viewed using a scanning electron microscope (SEM; JSM-5900LV, JEOL, Japan).

Cell migration assay

The cells were seeded in a six-well plate and cultured in the medium without fetal bovine serum (FBS) for 12 h. A plastic cell scraper was used to mark the vertical damage area (about 200 µm width) on the cells in each well. The experimental group was cultured with Mg alloy extract diluted four times with medium. After 0, 24, 48 and 96h, the healing of the scratches was observed under an inverted phase-contrast microscope (CK2, Olympus, Japan) and recorded. ImageJ software was used to analyse the images. Three parallel experiments were done, and data were presented as mean ± standard deviation (SD).

Real-time quantitative polymerase chain reaction detecting system

Total RNA was extracted from the cells with or without treatment by using the TRIzol reagent (Invitrogen Company, USA) according to the manufacturer’s instruction. The quantity was checked by NANO DROP (Thermo, USA). The first-strand cDNA was synthesized by reverse transcription using RNA as a template. Sequences of the primers are listed in Table 1 (Sangon Biotech Company,
Table 1. Oligonucleotide primers used for QRT-PCR (human) analysis

| Target transcript | Primer sequence (5'-3') |
|-------------------|------------------------|
| Rho A (forward)   | 5'-CTGTCCCAACGCTGCCCATATC-3' |
| Rho A (reverse)   | 5'-CACCAGGCTCCTGTCTCTATCT-3' |
| RAC 1 (forward)   | 5'-TGTTGACGAGGAGGTGAGTATGG-3' |
| RAC 1 (reverse)   | 5'-AGGAGCTGTCGATAGCTGTTCC-3' |
| CDC 42 (forward)  | 5'-GCCGTGACCTGAGGCTGCTC-3' |
| CDC 42 (reverse)  | 5'-ACCCAGCAGCCTAGCTCTCATC-3' |
| Paxillin (forward)| 5'-CACCAGGAGGCTGAGGTGAGTATGG-3' |
| Paxillin (reverse)| 5'-GCCAGGAGGCTGAGCTGCTC-3' |
| Vinculin (forward)| 5'-AAAATGACAGGGCTGGAGACACACC-3' |
| Vinculin (reverse)| 5'-CCTGCCACCCAGCACAAT-3' |
| β-Actin (forward) | 5'-GGCAGGGACTCGTAC-3' |
| β-Actin (reverse) | 5'-GAGGAGGCTGAGCTGCTC-3' |

The HCAECs were made into a cell suspension and evenly seeded on 14 mm round cell slides. When the confluence reached 90%, it was treated with 4-fold diluted Mg alloy extract for 24 h. After washing three times with PBS for 3 min, the samples were fixed with 4% paraformaldehyde for 30 min at room temperature, and then the samples were blocked in 5% goat serum with 0.1% triton for 30 min at room temperature. Ki67 (1:200), Paxillin (1:200) and Vinculin (1:200) primary antibodies (Table 2) diluted with 5% goat serum were incubated overnight at 4°C. After washing three times with PBS, FITC-labelled goat anti-rabbit IgG secondary antibody (1:1000) and TRITC-labelled goat anti-mouse IgG secondary antibody (1:1000) were incubated at room temperature for 1 h. After washing three times with PBS, the 4′/6-diamidino-2-phenylindole (DAPI) was diluted with PBS at a ratio of 1:1000, added into the samples and incubated at room temperature for 10 min. After washing with PBS four times, the samples were observed under confocal laser scanning with a confocal microscope (CLSM, Zeiss, Germany).

RNA-sequence

After culturing on the Mg alloy 24 h, the cells were collected. According to the manufacturer’s instruction, total RNA was extracted from the sample by using the Trizol reagent (Invitrogen Company). Before preparing the sequencing library by total RNA, agarose gel electrophoresis was used to detect quality control, and NANODROP measured the concentration of total RNA. Agilent 2100 was used for library quality control that was quantified by qPCR. Then Illumina Hiseq 4000 was used for sequencing. After using FastQC software to detect sequence quality, the abundance of transcripts in each sample was estimated by StringTie. The FPKM value (≥0.5) of genes and transcripts was assessed using the R package Ballgown. Then, differentially expressed genes and transcripts were filtered by R package Ballgown, and correlation analysis was processed.

Table 2. Primary antibody information

| Antibody (human) | Company | Catalog number | Description | Western blot |
|------------------|---------|----------------|-------------|-------------|
| Anti-β-actin     | Cell Signaling Technology | #3700 | Mouse monoclonal | 1:1000 |
| Anti-Ki67        | Cell Signaling Technology | #9449 | Mouse monoclonal | 1:800 |
| Anti-CDC 42      | Abcam   | ab187643       | Rabbit monoclonal | 1:10 000 |
| Anti-Rho A       | Abcam   | ab187027       | Rabbit monoclonal | 1:500 |
| Anti-RAC 1       | Abcam   | ab33186        | Mouse monoclonal | 1:100 |
| Anti-Paxillin    | Abcam   | ab32084        | Rabbit monoclonal | 1:500 |
| Anti-Vinculin    | Abcam   | ab129002       | Rabbit monoclonal | 1:10 000 |

Statistical analysis

All experimental data are expressed as mean ± SD. SSPS and Graphpad software were used for statistical analysis. Statistical significance was determined using one-way analysis of variance followed by Tukey’s test or two-tailed unpaired t-test. At least three independent experiments were performed for all biochemical experiments, and the representative images were shown. ∗P < 0.05 denotes statistically significant difference compared to control; ∗∗P < 0.01 denotes highly significant difference compared to control; ∗∗∗P < 0.001 denotes extremely significant difference compared to control; n.s. denotes no significant difference.
Availability of data and material
Gene expression profile data have been deposited for public access in the NCBI Gene Expression Omnibus under Accession Number (GSE146167). All data needed to evaluate the conclusions in the paper are present in the paper. Additional data related to this article may be requested from the authors.

Results and discussion
The degradation of Mg alloy in vivo and in vitro
The performance of an Mg alloy stent is primarily determined by its degradation in vivo. Therefore, we initially measured Mg alloy’s degradation in artificial plasma and subcutaneous tissue of male rats. In artificial plasma, Mg alloy’s corrosion was relatively faster than in subcutaneous tissue (Fig. 1A and B). It indicated that the Mg alloy used in this study had well corrosion resistance in vivo; it was lined with the successful application of Magmaris\textsuperscript{\textregistered} stent [22].

Energy dispersive spectrometer was used to measure the composition of Mg alloy surface elements after implantation in subcutaneous tissue at the indicated time. The concentration of the Mg element decreased on the surface (Fig. 1C); on the other hand, phosphorus (P) and calcium (Ca) had deposited on the surface (Fig. 1C). It suggested that the conversion of Mg phosphate to calcium phosphate occurred during the degradation of Mg alloy.

Mg alloy had good biocompatibility for ECs
To further validate the biocompatibility of Mg alloy, we conducted immunostaining and western blot to examine the expression and location of Ki67, which was relevant to cell proliferation [27]. The location of Ki67 in HCAECs after exposing to Mg alloy extract medium (thereafter was referred to as Extract-ECs, HCAECs cultured in the standard medium was referred to as Control) was detected, and no translocation was observed (Fig. 2A and B). Western blot band showed that the expression of Ki67 had no significant difference (Fig. 2C). It revealed that Ki67 had a stable expression and location in HCAECs with or without extract medium treatment. Furthermore, the viability of Extract-ECs was measured by CCK-8 analysis. The viability of Extract-ECs was similar to the Control group (Fig. 2D). Collectively, the results showed that Mg alloy had good biocompatibility to HCAECs.

Global gene expression profile of HCAECs subjecting to Mg alloy
We next sought to investigate how the Mg alloy dysregulated the migration and adhesion of HCAECs. Therefore, we conducted global gene expression profiling of HCAECs cultured on Mg alloy discs after 24 h (referred to as Mg-ECs, cells cultured on the dish are referred to as Control). The top 20 significantly changed genes are shown in Fig. 3A. Biological process (BP) enrichment analysis revealed the down-regulated adhesion and migration ability of HCAECs affected by Mg alloy (Fig. 3B and C). Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed signal pathways

Figure 1. The degradation of Mg alloy in vivo and in vitro. (A, B) The surface morphologies of degraded discs in medium and subcutaneous tissue at different duration, scale bar = 50 μm. (C) EDS was used to measure the composition of Mg alloy surface elements after implanting in subcutaneous tissue at the indicated time. Data were presented as mean ± SD; statistics were performed using one-way analysis of variance followed by Tukey test, ***P < 0.001.
related to cell adhesion and migration changed significantly (Fig. 3D). Heat map showed the differently expressed genes involved in adhesion and migration (Fig. 3E and F); the detailed gene list is shown in Tables 3 and 4.

Mg alloy inhibited the adhesion ability of HCAECs
To validate the results from RNA-seq, we examined adhesion morphology and expression of adhesion-related genes in Extract-ECs. HCAECs exhibited a spreading morphology cultured in dishes, while it had contractive morphology when seeded on Mg alloy discs (Fig. 4A). Focal adhesions (FAs) are required for cells spreading and adhesion. Accordingly, we measured the dynamics of several core FAs proteins. Adhesion proteins can be separated into distinct ‘modules’ based on their different functions [28]. The ‘signalling module’ protein Paxillin was down-regulated at the gene level while had a faint change at the protein level (Fig. 4B and D). As the ‘structural module’, Vinculin, which is essential for cell adhesion and spreading, decreased at the gene level and elevated little at protein level (Fig. 4C). It was in agreement with the contractive morphology of

Figure 2. The effect of Mg alloy extract on the proliferation of endothelial cells. (A) The distribution and expression of Ki67 in HCAECs with or without Mg alloy extract medium treatment were observed by CLSM. (blue: DAPI; red: F-actin; green: Ki67; scale bar = 10 μm). (B) Co-localization of Ki67 and nuclear was measured by ImageJ software. (C) The protein expression of Ki67 was detected by western blot analysis. β-Actin was used as the internal control (n = 3). (D) The viability of HCACEs was examined by using CCK-8. Data are presented as mean ± SD; statistics were performed by two-tailed unpaired t-test, n.s. denotes not significant.
HCAECs seeded on the Mg alloy discs. The immunostaining further confirmed the down-regulated expressions of Paxillin and Vinculin (Fig. 4E and F).

Mg alloy reduced the migration ability of ECs

Aiming to investigate Mg alloy’s effect on HCAECs motility, we performed a wound-healing assay and found that Mg alloy repressed HCAECs motility. The Mg alloy extract medium retarded the migration of HCAECs compared with the normal medium (Fig. 5A). RAC 1, Rho A, CDC 42 are essential members in Rho GTPases and control cell motility [29]. Western blot was conducted to measure the expression of RAC 1, Rho A and CDC 42 in Extract-ECs. The results showed that Mg alloy reduced the expressions of CDC 42 and Rho A, while RAC 1 had stable expression (Fig. 5B). It was supported by the real-time quantitative polymerase chain reaction (qRT-PCR) expression results (Fig. 5C–E). The above data indicated that Mg alloy down-regulated Rho GTPases’ expression, which resulted in the decreased migration ability.

Mg alloy stent retarded the complete re-endothelialization in vivo

Rapid EC coverage of the stent is required for avoiding thrombosis and late restenosis. Here, we conducted stent implantation in the rabbit artery to access the re-endothelialization of Mg alloy stent. A completed ECs layer was mainly finished in 2 weeks on stainless steel stent, while re-endothelialization was suppressed by the Mg alloy stent (Fig. 6A). Mg alloy’s degradation caused the composition

---

**Figure 3.** Mg alloy regulated gene expression associated with adhesion and migration. (A) Top 20 significantly changed genes detected by RNA-seq in HCAECs seeded on Mg alloy discs compared with HCAECs (up-regulated coloured red, down-regulated coloured green). (B, C) BP analysis of differently expressed genes in HCAECs seeded on Mg alloy discs compared with HCAECs. (D) KEGG enrichment pathway analysis for changed pathway associated with adhesion and migration in HCAECs seeded on Mg alloy discs compared with HCAECs. (E, F) Differently expressed genes involved in adhesion and migration detected by RNA-seq were shown in the hierarchical diagram in HCAECs seeded on Mg alloy discs compared with HCAECs.
| Gene name | Fold change (up-regulated) | Gene name | Fold change (up-regulated) |
|-----------|---------------------------|-----------|---------------------------|
| STC1      | 24.27777                  | FLCN      | 2.685                     |
| IGFBP3    | 13.64642                  | CIB1      | 2.637667                  |
| CEMIP     | 10.31747                  | HRH1      | 2.636922                  |
| AGTR1     | 10.01508                  | TP33IP1   | 2.633842                  |
| CITED2    | 8.278024                  | LGALS3    | 2.626668                  |
| VEGFA     | 7.57256                   | HBGF      | 2.609182                  |
| SERPINE1  | 7.133048                  | MDM2      | 2.599837                  |
| LOXL2     | 6.570949                  | MATN2     | 2.587203                  |
| NOV       | 5.729413                  | PRSS3     | 2.547352                  |
| BTG1      | 5.496675                  | ARHGEF2   | 2.545455                  |
| MMP1      | 5.404093                  | CD58      | 2.531493                  |
| ATP1B1    | 5.13255                   | CXCL8     | 2.487225                  |
| JUN       | 4.843613                  | KRT16     | 2.465552                  |
| F3        | 4.646604                  | SLC16A3   | 2.458289                  |
| TNS1      | 4.501898                  | SOX9      | 2.456554                  |
| L1CAM     | 4.325589                  | SNAI2     | 2.442667                  |
| DNER      | 4.096347                  | DDR1      | 2.440238                  |
| TNFRSF10D | 3.979881                  | CCL20     | 2.375038                  |
| SPOCK1    | 3.970137                  | C16or45   | 2.365153                  |
| ITGA2     | 3.893582                  | SPRY2     | 2.35184                   |
| TNFAIP6   | 3.857849                  | SCARB1    | 2.341672                  |
| LAMC2     | 3.687884                  | SFRP1     | 2.339137                  |
| CXCR4     | 3.580333                  | BMP2      | 2.33049                   |
| IRG2      | 3.526425                  | SPI00     | 2.330621                  |
| TNFSF12   | 3.316922                  | ACVR1     | 2.323221                  |
| LRP1      | 3.315323                  | TNFRSF10B | 2.288293                  |
| PRKCA     | 3.285778                  | DDIT4     | 2.256368                  |
| SDC4      | 3.201197                  | SEMA4B    | 2.25138                   |
| SBK2      | 3.19182                   | HDAC5     | 2.248255                  |
| KLF4      | 3.17761                   | ITGB3     | 2.243382                  |
| MYYADM    | 3.162549                  | AXL       | 2.195178                  |
| SH3KB1P1  | 3.146679                  | FGD1A     | 2.182462                  |
| SPNS2     | 3.128461                  | RHOB      | 2.175154                  |
| ITGA5     | 3.119477                  | VEGFC     | 2.153568                  |
| TGFBR1    | 3.118993                  | SDC2      | 2.147865                  |
| ITGB4     | 3.093541                  | TGFBI     | 2.146995                  |
| NR4A2     | 3.081555                  | CEND1     | 2.146292                  |
| CSAR1     | 3.048049                  | TRIB1     | 2.138017                  |
| PDGFB     | 3.040635                  | APP       | 2.120378                  |
| PTK6      | 2.872739                  | BST2      | 2.099677                  |
| EGFR      | 2.821483                  | PTGS2     | 2.095865                  |
| COL5A1    | 2.787228                  | BSG       | 2.092701                  |
| ITGA3     | 2.785423                  | VEGFB     | 2.079217                  |
| GPI       | 2.769742                  | BMP4      | 2.076694                  |
| DUSP10    | 2.72474                   | TREM1     | 2.068193                  |

(continued)
change of the stent surface, which might arrive at an unfriendly ion level for the ECs (Fig. 6B).

Conclusions

Percutaneous coronary artery intervention associated with stents is most widely accepted as an effective and safe treatment for single vessel and multi-vessel coronary atherosclerotic disease. Although BMS impedes restenosis dramatically compared to balloon angioplasty in the last decades, restenosis incidence still arrives 20–30% [30]. Therefore, DES had been used, and the rate of restenosis (5–10%) could be lower than BMSs [30]. The metallic materials of BMS and DES were kept in the vessel forever, although the drug was eluted and the polymer coat was degraded. Permanent vessel caging impairs arterial physiology, and the probability of very LST, though the occurrence probability is very low [31]. Because of its degradation properties in the physiological environment, the degradable stent was recently attracted much attention.

As a new material with high biocompatibility and excellent mechanical properties, the degradable Mg alloy material has been focussed on its potential application in the generation of biodegradable stents [17]. The rapid corrosion of Mg alloy material is one of the main constraints to its clinical application, although the Magmaris® stent has been successfully used [22]. Therefore, extensive studies have focussed on inhibiting stent corrosion and improving the mechanical properties of Mg-based alloy stents [32]. The main degradation product, Mg$^{2+}$, which is one of the most abundant intracellular cations, takes part in various vital cellular reactions to influence the viability and proliferation of HCAECs [33]. The Mg salt solution, such as MgCl$_2$, was used to measure the effect of Mg alloy degradation elements on vascular cells [24]. However, a variable concentration of Mg salt solution was used in the past research [34]. It is not easy to specify the effect of Mg salt solution on the BP by choosing a specific concentration. On the other hand, ECs cultured in the Mg salt solution does not simulate the in vivo situation as the ECs directly contact the Mg alloy materials in vivo.

Therefore, we cultured ECs exposed to Mg alloy discs or extract medium 24 h to avoid the damage of degradation products in the constant pool to ECs. The genes got enough time to express differently and then keep relatively stable. Furthermore, the pH shift in Mg corrosion is another factor that may regulate gene expression of ECs [35]. Meanwhile, pH change happened during the cell culturing process [36]. The underlying biomolecular mechanism by which the pH shift in Mg corrosion regulates ECs gene expression is not well known.

In this study, we evaluated the effects of Mg alloy on the cellular responses of HCAECs. The rate of re-endothelialization depends on

| Gene name   | Fold change (up-regulated) | Gene name   | Fold change (up-regulated) |
|-------------|----------------------------|-------------|----------------------------|
| CCL5        | 1.803252                   | DPYSL3      | 1.512534                   |
| TIMP1       | 1.787133                   | PSEN1       | 1.310164                   |
| PLXNA2      | 1.776413                   | Gene name   | Fold change (down-regulated) |
| S100A2      | 1.734608                   | HIF1A       | 0.240812                   |
| FAM59B      | 1.76988                    | SEMA6B      | 0.235757                   |
| TNFRSF12A   | 1.763901                   | PKN3        | 0.258733                   |
| RTN4        | 1.761169                   | EMP2        | 0.318825                   |
| MAPK14      | 1.755461                   | KIF20B      | 0.337359                   |
| STK24       | 1.742037                   | SHTN1       | 0.348257                   |
| SDCBP       | 1.738339                   | ANLN        | 0.363631                   |
| CYP1B1      | 1.737953                   | PLXND1      | 0.367796                   |
| MIF         | 1.734608                   | IL1R1       | 0.401752                   |
| APC         | 1.734293                   | NUP93       | 0.411265                   |
| MAP3K3      | 1.699488                   | AMOTL2      | 0.416412                   |
| GNRH1       | 1.695838                   | ID1         | 0.417674                   |
| RAP2B       | 1.68903                    | HMGB1       | 0.422201                   |
| SLC9A1      | 1.688039                   | CIQBP       | 0.450745                   |
| PODXL       | 1.67678                    | STAT1       | 0.451953                   |
| SI100A2     | 1.672244                   | SMO         | 0.452743                   |
| ZMYND8      | 1.66521                    | CENPV       | 0.452901                   |
| SELPLG      | 1.661614                   | NUP188      | 0.467387                   |
| ANO6        | 1.653642                   | SEMA3A      | 0.502904                   |
| NOG         | 1.647961                   | SEMA4G      | 0.507607                   |
| GREM1       | 1.645635                   | CXCL5       | 0.536764                   |
| DDRGK1      | 1.64124                    | ZNF609      | 0.544623                   |
| ITGAX       | 1.634522                   | JAM3        | 0.546291                   |
| ABHGA4      | 1.632232                   | EDN1        | 0.553224                   |
| BMPR2       | 1.6207                     | NRTN        | 0.57845                    |
| NDRG4       | 1.61812                    | SEMA3C      | 0.579641                   |
| RAB13       | 1.61544                    | PAXIP1      | 0.616381                   |
| ADGRA2      | 0.628179                   | GIPC1       | 0.642236                   |
| PF4         | 0.635523                   | PKN2        | 0.644713                   |
| TMEM201     | 0.638581                   | LBP         | 0.648244                   |
| FERM1       | 0.640175                   | CXCL2       | 0.652023                   |
the ability of the cells to adhere, migrate, proliferate and so on [23]. We found that after 24-h incubation with Mg-Extract, the viability and proliferation rate of HCAECs had no significant adverse effects (Fig. 2). The expression profiles of genes related to cell adhesion and migration were altered when HCAECs were seeded on Mg alloy discs (Fig. 3B and C). We further investigated the change of cell morphology after seeding directly on the Mg alloy discs. HCAECs tend to be round when seeded on Mg alloy discs (Fig. 4A). The morphology changes might also indicate that degradation products of Mg alloy inhibited the spreading process. The expression of FAs components, including Paxillin and Vinculin, was detected, and our results indicated that their expressions were decreased (Fig. 4B–D). In addition, the extract-ECs showed decreased motility (Fig. 5A), which was associated with down-regulated migration-related genes (Fig. 5B–E). The results of in vivo experiments also indicated that re-endothelialization of the Mg alloy stent surface was not perfected. Taken together, we hypothesized that Mg alloy exacerbated the process of re-endothelialization by affecting the migration and adhesion of ECs, but the underlying mechanism remained to be studied.

| Gene name | Fold change (up-regulated) | Gene name | Fold change (up-regulated) |
|-----------|---------------------------|-----------|---------------------------|
| IGF2      | 3.353979                  | SMAD7     | 2.031479                  |
| CITED2    | 8.278024                  | EFNA5     | 2.01906                   |
| VEGFA     | 7.57256                   | HLA-E     | 2.006855                  |
| SERPINE1  | 7.133048                  | ZBTB7B    | 2.001766                  |
| SERPINE2  | 4.271194                  | FOXC2     | 1.954102                  |
| ARG2      | 4.040669                  | SOCS5     | 1.944846                  |
| SPOCK1    | 3.970137                  | STX3      | 1.893833                  |
| ITGA2     | 3.893582                  | NDNF      | 1.887539                  |
| PLXNA3    | 3.827364                  | S100A10   | 1.859606                  |
| MUC1      | 3.437202                  | ADORA2A   | 1.842497                  |
| CD55      | 3.315238                  | DMTN      | 1.83036                   |
| PRKCA     | 3.285778                  | CCL5      | 1.803232                  |
| SDC4      | 3.201197                  | PLXNA2    | 1.776413                  |
| KLF4      | 3.17761                   | EBI3      | 1.742559                  |
| MYADM     | 3.162549                  | CYP1B1    | 1.737953                  |
| ITGA5     | 3.119477                  | SOCS1     | 1.726588                  |
| ZBTB1     | 3.051579                  | CD164     | 1.720611                  |
| ITGA3     | 2.785423                  | IGBP2     | 1.710745                  |
| RUNX1     | 2.773166                  | GNRH1     | 1.695383                  |
| PPP1CB    | 2.733251                  | SLCA9I    | 1.688039                  |
| DUSP10    | 2.72474                   | MAPK7     | 1.680037                  |
| FLCN      | 2.685                     | PODXL     | 1.67678                   |
| CIB1      | 2.637667                  | GREM1     | 1.645635                  |
| LGALS3    | 2.626668                  | FXYD5     | 1.639516                  |
| CXCL8     | 2.487225                  | TNFSF9    | 1.616681                  |
| SOX9      | 2.456554                  | CD9       | 1.600961                  |
| SNAI2     | 2.442667                  | PDFPK1    | 1.573535                  |
| DDR1      | 2.440238                  | PRKAR1A   | 1.571276                  |
| TFRC      | 2.403466                  | DUSP3     | 1.569103                  |
| CD276     | 2.355959                  | NRP1      | 1.568169                  |
| PAG1      | 2.354704                  | LPXN      | 1.566536                  |
| LMO7      | 2.342407                  | DHPS      | 1.559871                  |
| SFRP1     | 2.339137                  | ZNF703    | 1.551496                  |
| BMP2      | 2.333049                  | PLXNB3    | 1.534637                  |
| LGALS1    | 2.259964                  | AGER      | 1.530005                  |
| RND1      | 2.164827                  | TSC1      | 1.526465                  |
| VEGFC     | 2.153368                  | RPS3      | 1.517731                  |
| TGFB1     | 2.146995                  | TESC      | 1.507311                  |
| ACER2     | 2.128129                  | BCL6      | 1.506574                  |
| CYTH1     | 2.093908                  | Gene name | Fold change (down-regulated) |
| FSTL3     | 2.080918                  | MAD2L2    | 0.64414                   |
| BMP4      | 2.076694                  | FERMT1    | 0.640175                  |
| BCL10     | 2.072502                  | ADAM9     | 0.595791                  |
| RARA      | 2.065234                  | PTPN6     | 0.568468                  |
| DPP4      | 2.057136                  | GSTP1     | 0.556946                  |
| GCNT2     | 0.543328                  | Gene name | Fold change (down-regulated) |
| SKP2      | 0.507553                  | FGA       | 0.32608                   |
| RAC3      | 0.475456                  | EPCAM     | 0.260532                  |
| TGFB2     | 0.333832                  | FGB       | 0.131485                  |
|           |                           |           | 0.128291                  |
Mg alloy is bioresorbable scaffold material, which is being investigated for medical applications because of its enhanced properties of biodegradability and biocompatibility, such as bone replacement [18, 37]. However, there are few studies about the use of Mg alloy in CVDs, such as atherosclerosis (AS), which has been claimed to be the most common cause of death worldwide [38]. One of the limitations of using Mg-based alloy is the uncontrollability of degradation in vivo because of the electrochemically active property of Mg alloy [39]. At present, researchers have done many kinds of studies on corrosion resistance. Biodegradable polymer coatings are used to provide temporary corrosion resistance to Mg alloy for both orthopaedic and cardiovascular applications [40]. Here, we investigate the potential application of Mg alloy from a biomolecular view. The gene expression profiles showed that Mg alloy pronouncedly altered the expression of genes related to cell adhesion and migration. However, Mg alloy did not inhibit the proliferation of ECs. It indicated that the delayed re-endothelialization...
caused by Mg alloy was likely dependent on the retarded migration and adhesion ability of ECs. Our results may provide new inspiration for improving the broad application of Mg alloy stent in coronary AS.

**Acknowledgements**

The authors thank Dong Wang of the Analytical & Testing Center of Sichuan University for help with SEM images.
Funding
This research was supported by the National Natural Science Foundation of China (11802190), National Key Research and Development Program (2016YFC1102200) and the 111 Project [The Program of Introducing Talents of Discipline to Universities (B16033)].

Conflict of interest statement. The authors declare that they have no competing interests. All authors have read and approved the final submitted manuscript.

Author contributions
Z.H. carried out the entire experimental work and drafted the manuscript. H.C.Y., N.Y.C. and L.Y. performed the animal experiments. Z.H. and M.L.X. B.Z. participated in western blotting and qRT-PCR. N.Y.C. and L.F.Z. participated in immunohistochemical and immunofluorescence staining. F.G.H. and X.Y.M. measured the degradation properties of Mg alloy. X.C. and R.F.L. made the statistical analysis. H.C.Y. and Y.B.W. led the project, designed the experiments and edited the manuscript.

References
1. Organization WH. Cardiovascular diseases (CVDs): fact sheet 2017. 2017.
2. Yahagi K, Kolodgie FD, Otsuka F et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol 2016;13: 79–98.
3. Fitzgibbon GM, Kafka HP, Leach AJ et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616–26.
4. Neumann F-J, Sousa-Uva M, Ahlsson A et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
5. Giacoppo D, Alfonso F, Xu B et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol 2020;75:2664–78.
6. Diaz JF, de La Torre JM, Sabate M et al. Spanish Cardiac Catheterization and Coronary Intervention Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2011). Rev Esp Cardiol 2012;65: 1106–16.
7. Omata F, Vorpahl M, Nakano M et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014;129:211–23.
8. Liang CY, Hu YC, Wang HS et al. Biomimetic cardiovascular stents for in vivo re-endothelialization. Biomaterials 2016;103:170–82.
9. Venkatraman S, Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J Control Release 2007;120:149–60.
10. Douglas G, Van Kampen E, Hale AB et al. Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Eur Heart J 2013;34:3378–88.
11. Torri S, Jinouchi H, Sakamoto A et al. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J 2020;41:786–96.
12. van Beusekom HMM, Saia F, Zindler JD et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007;28:974–9.
13. Zhan JK, Wang YJ, Wang Y et al. The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells. Can J Cardiol 2014;30:568–75.
14. Adriaensen T, Joner M, Godsall TC et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 2017;136: 1007–21.
15. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents—a cause for concern. Circulation 2007;115:1440–55.
16. Ong ATL, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. Eur Heart J 2005;26:640–4.
17. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. Int J Mol Sci 2011;12: 4230–70.
18. Chen Y, Xu Z, Smith C et al. Recent advances on the development of magnesium alloys for biodegradable implants. Acta Biomater 2014;10: 4561–73.
19. Stuiger MP, Pietak AM, Huadmai J et al. Magnesium and its alloys as orthopedic biomaterials: a review. Biomaterials 2006;27:1728–34.
20. Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. The Lancet 2013;381:836–44.
21. Haude M, Ince H, Abizaid A et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 2016; 387:31–9.
22. Bennett J, Hemptinne QD, Mccutcheon K. Magnamis resorbable magnesium scaffold for the treatment of coronary heart disease: overview of its safety and efficacy. Expert Rev Med Dev 2019;16:757–69.
23. Gillian D, Erik VK, Hale AB et al. Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification[J]. Eur Heart J 2013;34:3378–88.
24. Sternberg K, Gratz M, Koeck K et al. Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. J Biomed Mater Res B Appl Biomater 2012;100: 41–50.
25. Zhu D, Su Y, Young ML et al. Biological responses and mechanisms of human bone marrow mesenchymal stem cells to Zn and Mg biomaterials. ACS Appl Mater Interfaces 2017;9:27453–61.
26. Mao L, Shen L, Chen J et al. A promising biodegradable magnesium alloy suitable for clinical vascular stent application. Sci Rep 2017;7:46343.
27. Imazumi K, Suzuki T, Kojima M et al. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci 2020;111:23–35.
28. Sturchbury B, Atherton P, Tsang R et al. Distinct focal adhesion protein modules control different aspects of mechanotransduction. J Cell Sci 2017;130:1612–24.
29. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629–35.
30. Jukema JW, Verschuren JJ, Ahmed TA et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2011;9:53–62.
31. Indolfi C, De Rosa S, Colombo A. Bioreabsorbable vascular scaffolds—basic concepts and clinical outcome. Nat Rev Cardiol 2016;13:719–29.
32. Zhang B, Yao R, Maizt MF et al. Poly (dimethyl diallyl ammonium chloride) incorporated multilayer coating on biodegradable AZ31 magnesium alloy with enhanced resistance to chloride corrosion and promoted endothelialization. Chem Eng J 2020;127724.
33. Zhu D, You J, Zhao N et al. Magnesium regulates endothelial barrier functions through TRPM7, MagT1, and S1P1. Adv Sci (Weinh) 2019;6: 1901166.
34. Zhao N, Zhu D. Endothelial responses of magnesium and other alloying elements in magnesium-based stent materials. Metallomics 2015;7: 118–28.
35. Wang J, Liu L, Wu Y et al. Ex vivo blood vessel bioresorber for analysis of the biodegradation of magnesium stent models with and without vessel wall integration. Acta Biomater 2017;50:546–55.
36. Michl J, Park KC, Swietach P. Evidence-based guidelines for controlling pH in mammalian live-cell culture systems. Commun Biol 2019;2:144.
37. Erbel R, Di Mario C, Bartunek J et al.; PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. *Lancet* 2007;369:1869–75.

38. Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: successes, surprises, and future challenges. *Circ Res* 2016;118:531–4.

39. Purnama A, Hermawan H, Couet J et al. Assessing the biocompatibility of degradable metallic materials: state-of-the-art and focus on the potential of genetic regulation. *Acta Biomater* 2010;6:1800–7.

40. Degner J, Singer F, Cordero L et al. Electrochemical investigations of magnesium in DMEM with biodegradable polycaprolactone coating as corrosion barrier. *Appl Surf Sci* 2013;282:264–70.